---
title: "Tango Therapeutics Prices $566.5 Million Equity Offering at $30 Per Share; 30-Day Option Granted"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289379604.md"
description: "Tango Therapeutics priced a $566.5 million equity offering at $30 per share, including pre-funded warrants. The company raised funds via an underwritten public offering with J.P. Morgan and Leerink Partners. Net proceeds will support R&D, pivotal trials, commercialization preparation, and general corporate purposes. A 30-day option allows underwriters to purchase up to 3 million additional shares. Closing is expected on June 11, 2026."
datetime: "2026-06-10T21:23:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289379604.md)
  - [en](https://longbridge.com/en/news/289379604.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289379604.md)
---

# Tango Therapeutics Prices $566.5 Million Equity Offering at $30 Per Share; 30-Day Option Granted

Tango Therapeutics entered into an Underwriting Agreement with J.P. Morgan Securities and Leerink Partners for an underwritten offering of 18,166,667 common shares at $30.00 per share and pre-funded warrants for 1,833,395 shares at $29.999. The underwriters have a 30-day option to buy up to 3,000,009 additional shares. Net proceeds are estimated at approximately $566.5 million, with closing expected on June 11, 2026. The company plans to use the funds for R&D, its pivotal trial, commercialization preparation, and general corporate purposes.

**Agreement details:**

-   **Agreement type**: Underwriting agreement for public offering of common stock and pre-funded warrants
-   **Counterparty**: J.P. Morgan Securities and Leerink Partners, as representatives of the underwriters
-   **Signed / Effective**: Jun 09 2026 / same
-   **Duration / Termination**: At will
-   **Reason**: Fund R&D, pivotal trial, and commercialization prep

Original SEC Filing: Tango Therapeutics, Inc. \[ TNGX \] - 8-K - Jun. 10, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [TNGX.US](https://longbridge.com/en/quote/TNGX.US.md)
- [JPM.US](https://longbridge.com/en/quote/JPM.US.md)
- [JPMO.US](https://longbridge.com/en/quote/JPMO.US.md)
- [JPX.US](https://longbridge.com/en/quote/JPX.US.md)
- [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md)
- [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md)
- [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md)
- [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md)
- [8634.JP](https://longbridge.com/en/quote/8634.JP.md)
- [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md)
- [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md)

## Related News & Research

- [COFG Advisors LLC Takes Position in JPMorgan Chase & Co. $JPM](https://longbridge.com/en/news/289288412.md)
- [JPMorgan Chase (JPM) to Deploy AI Agents Across Its Banking Operations](https://longbridge.com/en/news/289214151.md)
- [REG - Bytes Technology Grp JPMorgan Chase & Co - Holding(s) in Company](https://longbridge.com/en/news/289440860.md)
- [FY2026 Earnings Forecast for JPM Issued By Erste Group Bank](https://longbridge.com/en/news/289589762.md)
- [Why Tango Therapeutics (TNGX) Is Up 33.9% After Highlighting Pancreatic Cancer Pipeline Data Prospects](https://longbridge.com/en/news/289140698.md)